The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
ApexOnco Front Page
Recent articles
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
ESMO and the Triple Meeting approach.
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.
Genmab acquires the Dutch biotech for $8bn.
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
